Latest News From Lumira Ventures

New Data Confirms Cardiac Dimensions’ Carillon® System Provides Acute Hemodynamic Efficacy in Patients with Functional Mitral Regurgitation

Jennifer Schram Cardiac Dimensions, Portfolio News, Press Release

MANNHEIM, Germany – April 26, 2019 — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments to address functional mitral regurgitation (FMR) in patients with heart failure (HF), presented new data confirming significant reduction in regurgitant volume …

Cardiac Dimensions Announces Positive Late-Breaking Results for Blinded Clinical Trial of Minimally Invasive Heart Failure Treatment

Ahmed Khan Cardiac Dimensions, Portfolio News

In Randomized Blinded Study, the Carillon Mitral Contour System Catheter-Based Treatment Meets Endpoint for Reduction in Regurgitant Volume KIRKLAND, Wash.- Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular …

Cardiac Dimensions Announces $39 Million Series B Financing for Innovative Device to Treat Patients With Heart Failure

Ahmed Khan Cardiac Dimensions, Portfolio News

KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for patients with heart failure, today announced the company has closed a $39 million Series B financing. The round includes new investor, Australia-based Hostplus, venture debt …

Cardiac Dimensions Announces Investigational Device Exemption Approval from FDA to Conduct U.S. Pivotal Study of the Carillon Mitral Contour System for Functional Mitral Regurgitation

admin Cardiac Dimensions, Portfolio News

Kirkland, WA – Dec. 1, 2016 – Cardiac Dimensions, the leader in minimally invasive repair therapies for functional mitral regurgitation (FMR), today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the pivotal …

Cardiac Dimensions Announces Appointment of Gregory D. Casciaro as President and Chief Executive Officer

admin Cardiac Dimensions, Portfolio News

KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a medical device company dedicated to addressing functional mitral regurgitation using an innovative, minimally invasive approach, today announced the appointment of Gregory D. Casciaro as President and Chief Executive Officer (CEO), effective immediately. Mr. Casciaro will …

Cost-Utility Analysis Projects CARILLON Mitral Contour System as a Cost Effective Treatment Option for Functional Mitral Regurgitation

admin Cardiac Dimensions, Portfolio News

SOURCE: BUSINESSWIRE September 09, 2015 05:00 AM Eastern Daylight Time KIRKLAND, Wash.–(BUSINESS WIRE)–The CARILLON® Mitral Contour System® is projected to be a cost-effective treatment option when compared to a typical regimen of optimal medical treatment (OMT), the present standard of care for functional …

Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System

admin Cardiac Dimensions, Portfolio News

Third Multi-Center Study Shows Compelling Results Consistent with Previous Trials; Data Presented at TCT     KIRKLAND, Wash., Sept. 17, 2014 /PRNewswire/ — Cardiac Dimensions®, Inc. today announced that new long-term outcomes data from the TITAN II clinical trial of …